Skip to main content
Top
Published in: PharmacoEconomics 2/2010

01-02-2010 | Editorial

We Know Accurately Only When We Know Little

Authors: Dr Stuart MacLeod, Craig Mitton

Published in: PharmacoEconomics | Issue 2/2010

Login to get access

Excerpt

Our title reflects a maxim penned by Goethe. It continues in translation to read ‘With knowledge doubt increases.’[1] The articles that appear in this issue stemming from a special symposium held in Banff (Alberta, Canada) in February 2009, describe our progress toward agreement on the concept of access with evidence development (AED).[26] Goethe’s reflection summarizes the dilemma. Much of decision making in healthcare is based on the premise that certainty can be achieved through randomized controlled trials (RCTs) and translated into policy decisions on issues such as insurance coverage. Unfortunately, we have become increasingly aware of the constraints imposed by reliance on evidence based solely on RCTs, and the healthcare system is now shifting rapidly toward the acceptance of other kinds of evidence to support a more nuanced form of decision making that gives appropriate weighting to the perspectives of patients, their families and their healthcare providers.[710] …
Literature
2.
go back to reference McCabe CJ. Principles of design of access with evidence development approaches: a consensus statement from the Banff summit. Pharmacoeconomics 2010; 28 (2): 109–11PubMedCrossRef McCabe CJ. Principles of design of access with evidence development approaches: a consensus statement from the Banff summit. Pharmacoeconomics 2010; 28 (2): 109–11PubMedCrossRef
3.
go back to reference Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010; 28 (2): 113–42PubMedCrossRef Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics 2010; 28 (2): 113–42PubMedCrossRef
4.
go back to reference McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics 2010; 28 (2): 143–52PubMedCrossRef McCabe CJ, Stafinski T, Edlin R, et al. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics 2010; 28 (2): 143–52PubMedCrossRef
5.
go back to reference Briggs A, Ritchie K, Fenwick E, et al. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics 2010; 28 (2): 163–70PubMedCrossRef Briggs A, Ritchie K, Fenwick E, et al. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics 2010; 28 (2): 163–70PubMedCrossRef
6.
go back to reference Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics 2010; 28 (2): 153–62PubMedCrossRef Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics 2010; 28 (2): 153–62PubMedCrossRef
7.
go back to reference Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290 (12): 1624–32PubMedCrossRef Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290 (12): 1624–32PubMedCrossRef
8.
go back to reference Garrison Jr LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR realworld data task force report. Value Health 2007; 10: 326–35PubMedCrossRef Garrison Jr LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR realworld data task force report. Value Health 2007; 10: 326–35PubMedCrossRef
9.
go back to reference Drummond M, Evans W, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases. A case study in oncology. Can J Clin Pharmacol 2009; 16 (2): e273–81PubMed Drummond M, Evans W, LeLorier J, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases. A case study in oncology. Can J Clin Pharmacol 2009; 16 (2): e273–81PubMed
10.
go back to reference Gooch KL, Smith D, Wasylak T, et al. The Alberta hip and knee replacement project: a model for health technology assessment based on comparative effectiveness of clinical pathways. Int J Tech Assess Health Care 2009; 25: 113–23 Gooch KL, Smith D, Wasylak T, et al. The Alberta hip and knee replacement project: a model for health technology assessment based on comparative effectiveness of clinical pathways. Int J Tech Assess Health Care 2009; 25: 113–23
11.
go back to reference MacLeod SM, Bienenstock J. Evidence-based rationing: Dutch pragmatism or government insensitivity? Can Med Ass J 1998; 158: 213–4 MacLeod SM, Bienenstock J. Evidence-based rationing: Dutch pragmatism or government insensitivity? Can Med Ass J 1998; 158: 213–4
12.
go back to reference Williams A. What could be nicer than NICE? London: Office for Health Economics, 2004 Williams A. What could be nicer than NICE? London: Office for Health Economics, 2004
13.
go back to reference Hightower J. Theres nothing in the middle of the road but yellow stripes and dead armadillos: a work of political subversion. New York: HarperCollins Publishers, 1997 Hightower J. Theres nothing in the middle of the road but yellow stripes and dead armadillos: a work of political subversion. New York: HarperCollins Publishers, 1997
14.
go back to reference Chalkidou K, Tunis S, Lopert R, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 2009; 87: 339–67PubMedCrossRef Chalkidou K, Tunis S, Lopert R, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 2009; 87: 339–67PubMedCrossRef
15.
go back to reference Eden J, Wheatley B, McNeil B, et al., editors. Committee on reviewing evidence to identify highly effective clinical services. Knowing what works in health care: a roadmap for the nation. Washington, DC: The National Academies Press, 2009 Eden J, Wheatley B, McNeil B, et al., editors. Committee on reviewing evidence to identify highly effective clinical services. Knowing what works in health care: a roadmap for the nation. Washington, DC: The National Academies Press, 2009
16.
go back to reference Lomas J. Commentary: whose views count in evidence synthesis? And when do they count? Healthc Policy 2006; 1 (2): 55–7PubMed Lomas J. Commentary: whose views count in evidence synthesis? And when do they count? Healthc Policy 2006; 1 (2): 55–7PubMed
17.
go back to reference Daniels N. Rationing fairly: programmatic considerations. Bioethics 1993; 7: 223–33CrossRef Daniels N. Rationing fairly: programmatic considerations. Bioethics 1993; 7: 223–33CrossRef
18.
go back to reference Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff 1998; 17: 50–64CrossRef Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff 1998; 17: 50–64CrossRef
19.
go back to reference Daniels N, Sabin JE. Setting limits fairly: can we learn to share medical resources? New York: Oxford University Press, 2002 Daniels N, Sabin JE. Setting limits fairly: can we learn to share medical resources? New York: Oxford University Press, 2002
Metadata
Title
We Know Accurately Only When We Know Little
Authors
Dr Stuart MacLeod
Craig Mitton
Publication date
01-02-2010
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 2/2010
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11531510-000000000-00000

Other articles of this Issue 2/2010

PharmacoEconomics 2/2010 Go to the issue

Conference Paper

Funding the Unfundable